Zotiraciclib
A cyclin-dependent kinase inhibitor
| Zotiraciclib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | |
| ChemSpider | 12345678 |
| KEGG | |
Zotiraciclib is an investigational cyclin-dependent kinase (CDK) inhibitor that has been studied for its potential use in the treatment of various types of cancer. It is known by its research code TG02.
Mechanism of Action[edit | edit source]
Zotiraciclib functions by inhibiting multiple cyclin-dependent kinases, which are enzymes that play a crucial role in the regulation of the cell cycle. By inhibiting these kinases, zotiraciclib can induce cell cycle arrest and promote apoptosis in cancer cells. This mechanism is particularly effective in rapidly dividing cells, such as those found in tumors.
Clinical Development[edit | edit source]
Zotiraciclib has been evaluated in several clinical trials to assess its efficacy and safety in treating different types of cancer, including glioblastoma and other solid tumors. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to cross the blood-brain barrier and target brain tumors effectively.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of zotiraciclib includes its absorption, distribution, metabolism, and excretion. The drug is administered orally and has been shown to have a favorable bioavailability. It is metabolized primarily in the liver and excreted through the kidneys.
Side Effects[edit | edit source]
As with many cancer therapies, zotiraciclib can cause a range of side effects. Common adverse effects observed in clinical trials include nausea, fatigue, and hematological toxicity, such as neutropenia and thrombocytopenia.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the dosing regimen of zotiraciclib and exploring its use in combination with other anticancer agents. Studies are also investigating biomarkers that may predict response to treatment, which could help tailor therapy to individual patients.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
